echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Leuk Res: High Bax/Bcl-2 ratio is associated with good prognosis and better survival in B-cell chronic lymphocytic leukemia patients

    Leuk Res: High Bax/Bcl-2 ratio is associated with good prognosis and better survival in B-cell chronic lymphocytic leukemia patients

    • Last Update: 2022-01-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Of all leukemias , chronic lymphocytic leukemia (CLL) is the most prevalent type in the global population


    Of all leukemias , chronic lymphocytic leukemia (CLL) is the most prevalent type in the global population


    Determination of the Bax/Bcl-2 ratio may be a good predictive tool for identifying the prognosis and prognosis of patients with chronic lymphocytic leukemia (CLL) to determine the timing and type of treatment, therefore, a prospective study of 100 newly diagnosed CLL patients was performed.


    Figure 1: CD49d, Bax and Bcl-2 detected by flow cytometry in 2 CLL patients


    Figure 1: CD49d, Bax and Bcl-2 detected by flow cytometry in 2 CLL patients


    The expression of Bax and Bcl-2 in peripheral blood was measured by flow cytometry


    Figure 2: Prediction of overall survival based on the ROC curve of the Bax/Bcl-2 ratio


    Figure 2: Prediction of overall survival based on the ROC curve of the Bax/Bcl-2 ratio


    Figure 3: Kaplan-Meier survival analysis using Bax/Bcl-2 ratio for A, overall survival (OS) and B, progression free survival (PFS)


    Figure 3: Kaplan-Meier survival analysis using Bax/Bcl-2 ratio for A, overall survival (OS) and B, progression free survival (PFS)


    By receiver operating characteristic (ROC) curve detection, the best Bax/Bcl-2 ratio for predicting survival was 1.


    The researchers concluded that a lower Bax/Bcl-2 ratio was associated with poorer prognosis, as evidenced by lower OS and PFS in CLL patients


    Original source:

    Original source:

    Helaly NA, Esheba NE, Ammo DEA, Elwan NM, Elkholy RA.


    Helaly NA, Esheba NE, Ammo DEA, Elwan NM, Elkholy RA.
    High Bax/Bcl-2 ratio is associated with good prognosis and better survival in patients with B cell chronic lymphocytic leukemia.
    Leuk Res.
    2021 Aug;107:106604.
    doi : 10.
    1016/j.
    leukres.
    2021.
    106604.
    Epub 2021 Apr 30.
    PMID: 33965850.
    Helaly NA, Esheba NE, Ammo DEA, Elwan NM, Elkholy RA.
    High Bax/Bcl-2 ratio is associated with good prognosis and better survival in patients with B cell chronic lymphocytic leukemia.
    Leuk Res.
    2021 Aug;107:106604.
    doi: 10.
    1016/j.
    leukres.
    2021.
    106604.
    Epub 2021 Apr 30.
    PMID: 33965850.


    Leave a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.